Key clinical point: The drug’s approval provides a considerable opportunity to lower cost of treatment and expand treatment options.
Major finding: Results achieved following 24-week intermittent treatment regimen.
Study details: Letter to the editor; 40 patients evaluated in observational, retrospective, single-center study.
Disclosures: The authors reported serving as consultants and speakers for AbbVie, Biogen, Eli Lilly, Janssen, Pfizer, and Novartis.
Giunta A et al. Br J Dermatol. 2019 May 3. doi: 10.1111/bjd.18090.